Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Raghunath

This Surging Small-Cap Biotech Has One Very High-Profile Investor

One of the hottest stocks in 2024 is Humacyte (HUMA), which has surged 163% year-to-date. Valued at $890 million by market cap, Humacyte is engaged in the business of developing and manufacturing implantable, bioengineered human tissues, advanced tissue constructs, and organ systems. 

Despite its stellar returns in 2024, Humacyte stock is down 56% from all-time highs, allowing you to buy the dip. Let’s see what’s driving Humacyte stock higher in recent months. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.